Table 1.

Selenocoxib-1-GSH kills melanoma cells more effectively than normal cells

FOM103FF2441WM35WM115UACC 9031205 Lu
Celecoxib>100>10051.3 ± 2.354.4 ± 3.6>100>10024 h
Selenocoxib-1 -GSH66.3 ± 3.0>10052.6 ± 3.830.1 ± 3.330.9 ± 2.824.6 ± 2.2
Celecoxib>100>10042.3 ± 1.845.3 ± 2.7>10083.6 ± 3.348 h
Selenocoxib-1 -GSH53.4 ± 4.375.5 ± 5.64.1 ± 0.85.8 ± 0.920.6 ± 1.717.2 ± 1.6
Celecoxib68.0 ± 1.265.3 ± 3.337.9 ± 3.341.8 ± 2.976.6 ± 4.466.1 ± 3.272 h
Seleriocoxib-1 -GSH41.2 + 3.236.3 ± 5.62.7 ± 0.43.1 ± 0.414.2 ± 1.210.6 ± 2.6
NormalRadialVerticalMetastatic

NOTE: Normal and melanoma cells were seeded in to a 96-well plate and, after 36 to 72 hours, treated with increasing concentrations of celecoxib, selenocoxib-1, or selenocoxib-1-GSH for the indicated time period. Number of viable cells was measured using MTS and percentage decrease in viability calculated. IC50 values for each inhibitor in μmol/L for respective cell lines were measured from 3 independent experiments using GraphPad Prism version 4.01 (GraphPad Software, La Jolla, CA).